IITDLogo
Bacteriophage research and therapy - Other publications
  1. Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds, Mendes JJ, Leandro C, Corte-Real S, Barbosa R, Cavaco-Silva P, Melo-Cristino J, Górski A, Garcia M, Wound Repair Regen. 2013,21,595-603
  2. Tackling antibiotic resistance, Bush K, Courvalin P, Dantas G et al., Nature Rev Microbiol 2011,9,894-6,
    "The investigation of novel non-antibiotic approaches for the prevention of and protection against infectious diseases should be encouraged, and such approaches must be high-priority research and developmental projects. These approaches include the use of antibacterial vaccines, phage therapy, immunostimulants, adjuvants, antivirulence therapies, probiotics and their combinations."
  3. Extraordinary measures: Arrowsmith for the NASDAQ era, G.Weissmann, FASEB J 2010,24,963-7
    "Phage is crawling back as a therapy, as Joshua Lederberg predicted a decade and a half ago."
  4. A quarter of patients in some European hospitals acquire infections, R.Watson, BMJ 2010,341:c6700
  5. Bacteriophages: therapeuticals and alternative applications, Van der Vlugt RAA, Verbeek M, COGEM Research Report No. CGM 2008-03,
    available at: http://www.cogem.net/ContentFiles/CGM%202008-03%20Bacteriofagen1.pdf
  6. Bacteriophages, Vaneechoutte, M., M. Merabishvili, G. Verbeken, D. De Vos, and J. P. Pirnay, In: Alternatives to antibiotics. Dutch Ministry of Agriculture, Nature and Food Quality, 2009, 53-71.
  7. The rise and rise of Staphylococcus aureus: laughing in the face of granulocytes, Anwar S, Prince LR, Foster SJ, Whyte MK, Sabroe I., Clin Exp Immunol 2009,157,216-24
  8. Läkartidningen - Fagterapi kan vara räddningen när antibiotika ...
  9. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy , Wright A, Hawkins CH, Anggard EE, Harper DR, Clin Otolaryngol. 2009;34(4):349-57
  10. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial , Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A, J Wound Care. 2009,18(6):237-8, 240-3
  11. Phage therapy. JN Housby, Drug Disc Today 2009,14,536-40
    "...further expansion of phage therapy as an experimental treatment in accord with current international standards (written informed consent, approval by an institutional review board, and the necessary insurance policies - an approach implemented at the Wroclaw Institute in the past three years) could be considered in cases when antibiotics fail."
  12. Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge, Cesar A. Arias, Barbara E. Murray, The New England Journal of Medicine 2009,360:439-443
  13. The bacteria fight back. In their ongoing war against antibiotics, the bacteria seem to be winning and the drug pipeline is verging on empty, G.Taubes, Science 2008,321,356-61
  14. Battle against antibiotic resistance is being lost, K.Morris, Lancet Infect Dis 2007,7,509
    "Antibiotics resistance is an increasingly serious problem... At the present time microbes are beating medicine".

    "S.aureus isolates have now been identified that are vancomycin-intermediate and vancomycin-resistant... There are no new antibiotics on the horizon that will be effective in treating the more resistant S.aureus".
  15. Phage therapy: everything old is new again, AM Kopinski, Can J Infect Dis Med Microbiol 2006,17,297-306
    The most clearly documented phage therapeutic research - and the most relevant to the global problem of antimicrobial resistance - was conducted at the Institute of Immunology and Experimental Therapy (also known as the "Hirszfeld Institute") in Wroclaw, Poland... These studies have been described as the "most detailed studies published in English on the use of phages in clinical settings" and "probably the most important data published in the English literature".
  16. The apparent success of phage treatment for plague plays a key part in the novel. The book invocation of the potential of phage straddles the line between fiction and reality, Robert Bud. Arrowsmith, by Sinclair Lewis, Br Med J 2007,334,539
  17. European regulatory conundrum of phage therapy, Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay JP, Future Microbiol. 2007 Oct;2:485-91
  18. Attempts to treat infected wounds with bacteriophages, Witoszka M, Strumiłło B, Pol. Przegl. Chir.1963,35,10-11 (Polish Surg. Rev) (in Polish)
    "... we noted improvement in 35 of of 50 patients treated. This corresponds to the results achieved in the treatment of staphylococcal infections resistant to common chemotherapeutics and therefore treated with very expensive antibiotics".
    I Surgical Department, The Medical University of Warsaw.
     
  19. Bacteriophages: an appraisal of their role in the treatment of bacterial infections, Hanlon GW, Int J Antimicrob Agents 2007, 30, 118-28
  20. Bacteria-eating viruses approved as food additive, FDA Consumer Magazine, Jan-Feb 2007,
    http://www.fda.gov/fdac/features/2007/107_virus.html
  21. Anti-infective research and development - problems, challenges, and solutions. Rubinstein E, Zhanel GG, Lancet Infect Dis 2007,7,68-78.
    "Lack of new antibiotics requires re-evaluating and re-investing in... bacteriophages..."
  22. FDA approves use of bacteriophages to be added to meat and poultry products, LH Lang, Gastroenterology 2006,131,1370
  23. Reinventing phage therapy: are the parts greater than the sum? Fischetti VA, Nelson D, Schuch R, Nat Biotechnol. 2006,12,1508-11.
  24. Efficacy of Bacteriophage Therapy against Pseudomonas aeruginosa gut-derived Sepsis in Mice, Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, Uchiyama J, Sakurai S, Matsuzaki S, Imai S, Yamaguchi K, Antimicrob Agents Chemother. 2006 Nov 20
  25. Declaration of Helsinki, http://www.wma.net/e/policy/b3.htm:
    1. In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist or have been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, these measures should be made the object of research, designed to evaluate their safety and efficacy. In all cases, new information should be recorded and, where appropriate, published. The other relevant guidelines of this Declaration should be followed.
  26. The road to phage therapy. S.Adhya, C.Merril, Nature 2006,443,754-5.
    "An anectodal approach, adopted by some investigators... may retard rather than stimulate the acceptance of therapeutic applications".
  27. Najpoważniejszy dziennik szwedzki, Dagens Nyheter, o ośrodku terapii fagowej naszego Instytutu:
    http://www.dagensnyheter.se/DNet/jsp/polopoly.jsp?a=573602
  28. Nauka dla przyszłości, A.Wolski, Forum Akademickie 2006,7-8,60-61.
  29. U.S. needs to open eyes to 'phage therapy'
    USA Today, 6 July 2006. A. Kantor
  30. A CLOSER LOOK: ANTI-LISTERIA SPRAY
    Latest food additive: Viruses
    The FDA-approved bacteria eaters work on deli meats and other ready- to-eat foods.

    HE McGregor, Los Angeles Times, 28/08/2006, p. F1.
    "... everybody says stay away from viruses, and now we are eating them"
  31. Multiplication of therapeutically administered bacteriophages in Psedomonas aeruginosa infected patients, JA Sivera Marza, JS Soothill, P.Boydell, TA Collins, Burns 2006,32,644-646
  32. Bakteriofagi z... Wrocławia
    Polska Akademia Nauk o Ośrodku Terapii Fagowej przy Instytucie Immunologii i Terapii Doświadczalnej PAN we Wrocławiu
  33. Bakteriofagi: polskie antidotum na zakażenia bakteryjne, Nauka w Polsce (serwis PAP poświęcony polskiej nauce, finansowany przez Ministerstwo Nauki i Szkolnictwa Wyższego)
  34. Bug killers, T.Hausler, Nature Medicine 2006,12,600-601
  35. Bacteriophage in the treatment of chronic wounds, R.Wolcott, J.Fralick, B.Burrowes, Texas Tech Univ Health Sciences, Lubbock, TX, USA,
    1st Texas/Evergreen Phage/Virus Genomics and Ecology Meeting, May 12-16, Kingsville, TX. Abstracts, p.11.
  36. The Tripartite Associations between Bacteriophage, Wolbachia, and Arthropods,
    Seth R. Bordenstein, Michelle L. Marshall, Adam J. Fry, Ulandt Kim, Jennifer J. Wernegreen, PLoS Pathog May 19, 2006
  37. Use of phages in therapy and bacterial detection, McKinstry M, Rotem, E., In: Phages: their role in bacterial pathogenesis and biotechnology, (Waldor MK, Friedman DI, Adhya, SL, eds). ASM Press, Washington, D.C., 2006, pp.430-440
  38. Phage therapy, Merril CR, Scholl D, Adhya, S., In: The bacteriophages, (Calendar R, ed), Oxford University Press, 2006, pp.725-741
  39. Phage therapy: facts and fiction, Skurnik M, Strauch E., Int.J.Med.Microbiol. 2006,296,5-14
  40. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases, Shigenobu Matsuzaki, Mohammad Rashel, Jumpei Uchiyama, Shingo Sakurai, Takako Ujihara, Masayuki Kuroda, Masahiko Ikeuchi, Toshikazu Tani, Mikiya Fujieda, Hiroshi Wakiguchi, Shosuke Imai, J Inf Chemother 2005,11,211-219
  41. Independent clinical research in Europe, G.Remuzzi, A.Schieppati, J.P. Boissel, S.Garattini, R.Horton, The Lancet 2004,364,1723-1726
    "The pharmaceutical industry is driving clinical research
    There is a gap between the development of new drugs and patients' real interests. As an example, in 2002, of 89 drugs newly approved by the US Food and Drug Administration (FDA), none were antibiotics, and only nine new antibiotics have been approved since 1998, while the resurgence of old killers such as tuberculosis and the emergence of infections resistant to existing antimicrobal agents pose a global threat to health."
  42. Bacteriophage Esc-A is an efficient therapy for Escherichia coli 3-1 caused diarrhea in chickens, Xie H, Zhuang X, Kong J, Ma G, Zhang H, J Gen Appl Microbiol. 2005,51(3),159-63
    "The bacteriophage Esc-A was isolated from sewage by using the intestinal pathogenic Escherichia coli 3-1 as the host. Toxicity in chickens showed its safety as a bio-product. Phage therapy against diarrhea in chickens indicated that Esc-A could decrease the death rate more efficiently compared with antibiotic treatments"
  43. Georgia: an unlikely stronghold for bacteriophage therapy, Tom Parfitt, The Lancet 2005,365,2166-2167
  44. Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy, Bruttin A, Brussow H, Antimicrob Agents Chemother 2005,49,2874-8
  45. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections, Sulakvelidze A, Drug Discov Today 2005,10,807-9
  46. The fd phage and a peptide derived from its p8 coat protein interact with the HIV-1 Tat-NLS and inhibit its biological functions, Krichevsky A, Rusnati M, Bugatti A, Waigmann E, Shohat S, Loyter A, Antiviral Res. 2005,66,67-78
  47. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals, O'Flaherty S, Ross RP, Meaney W, Fitzgerald GF, Elbreki MF, Coffey A, Appl Environ Microbiol. 2005,71(4),1836-42
    "...propagation of phage K on these less-sensitive strains resulted in all 14 being sensitive to the modified phages. The results enforce the principle that, while certain target bacteria may be relatively insensitive to lytic phage, this can be overcome by obtaining modified phage variants from passage of the phage through the insensitive strains."
  48. Experimental Bacteriophage Protection against Staphylococcus aureus Abscesses in a Rabbit Model, Wills QF, Kerrigan C, Soothill JS, Antimicrob Agents Chemother. 2005,49,1220-1
    "In a rabbit model of wound infection caused by Staphylococcus aureus, 2 x 10(9) PFU of staphylococcal phage prevented abscess formation in rabbits when it was injected simultaneously with S. aureus (8 x 10(7) CFU) into the same subcutaneous site. Phage multiplied in the tissues. Phages might be a valuable prophylaxis against staphylococcal infection."
  49. Epidemics of cholera are inversely correlated with the prevalence of cholera phages in contaminated water, S. Amoils, Nature Rev Microbiol 2005,3,194
  50. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages, Faruque SM, Bin Naser I, Islam MJ, Faruque ASG, Ghosh AN, Nair GB, Sack DA, Mekalonos JJ, Proc. Natl. Acad. Sci. USA 2005,102,1702-7
    "...disease incidence tracks inversely with the prevalence of lytic phages in the environment. We propose that phages play their predominant role in ending cholera epidemics... the absence of phages in the aquatic environment might promote cholera epidemics. Vibriophages might even be employed as biological control agents in cholera endemic areas."
  51. Phage therapy: where East meets West, J.Debattista, Expert Rev Infect Ther 2004,2,815-819
    "... host specific bacteriophages as a means of treating bacterial infection... has continued to attract interest as a potential alternative, or at least adjunct to conventional chemical bactericides... With the resurgence of public concern towards the spread of antibiotic resistance, it may prove timely for renewed consideration of the bacteriophage and its place within medicine's armamentarium"
    "... I can only hope that my meagre contribution to this exciting discussion about phage therapy has done justice to the remerkable work your Institute has achieved over many years. I would certainly like to add my voice to the congratulations your team deserves for their outstanding work in this field"
    Dr J.Debattista, The Prince Charles Hospital, Queensland Government, Queensland Health, Australia
  52. Therapeutic efficacy of bacteriophage and baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers, Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM, Poult Sci. 2004, 12, 1944-7
    "...bacteriophage combined with antibiotic treatment has significant value"
  53. Renaissance phage, Editorial: Renaissance phage, Nature Rev Microbiol 2004,2,922
    "The future looks bright for those who believe "all the word's a phage"."
  54. Viren als Verbuendete gegen Infektionen, Ulla Bettge, Die Welt, 6.12.2004
    "Polen habe in den vergangenen Jahrzehnten international die Fuehrung in klinischer Phagen-Therapie uebernommen"
  55. The Antibiotic Pipeline - Challenges, Costs, and Values, RP Wenzel, New Eng J Med 2004,351,523-526,
    "With increasing levels of antibiotics resistance, an insecure pipeline, and a dwelling number of companies investing in antiinfective agents, we have reached an unsettling impasse in medicine"
  56. In vitro antimicrobial effect of bacteriophages on human dentin infected with Enterococcus faecalis, AF Paisano, B Spira, S Cai, Bombana AC, Oral Microbiol Immunol. 2004,5,327-30
  57. Population and evolutionary dynamics of phage therapy, BR Levin, JJ Bull, Nature Rev Microbiol 2004,2,166-173,
    "We, like many others, believe there is sufficient scientific justification to study and develop the use of bacteriophage for therapy and prophylaxis"
  58. MRSA infection in children, LANCET 2004,363,1047,
    "Rates of meticillin-resistant S.aureus bacteraemia in children in England and Wales has increased 19-fold between 1990 and 2001."
  59. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase, Kim DH, Longo M, Hanch Y et a., Nature Biotechnol 2004 (in press)
  60. New dawn for phage therapy, B.Dixon, Lancet Infect Dis 2004, 4, 186,
    "A few tenacious medics in Poland ... have also continued to believe that phage therapy has a valid place in dealing with certain human pathogens."
  61. My enemy's enemy is my friend. Using phages to fight bacteria, J.Bradbury, LANCET 2004, 363, 624-625
  62. Antibiotic use in relation to the risk of breast cancer, Ch M Velicer, SR Heckbert, JW Lampe, et al. JAMA 2004,291,827,
    "Use of antibiotics is associated with increased risk of incident and fatal breast cancer."
  63. Antimicrobial drug discovery through bacteriophage genomics, Liu J, Dehbi M, Moeck G, Nature Biotechnology 2004 (in press)
  64. Antibiotics spread resistance?,
    Lancet 2004,363,49 (Beaber JW et al, Nature 2004,427,72)
  65. Old dogma, new tricks - 21st Century phage therapy, K. Thiel, Nature Biotechnology, 2004, 22, 31-36
  66. The day of the phage, JP Clewley, Commun Dis & Public Hlth 2003,6,260-262,
    "...recent advances... have made phage therapy a more viable proposition... Has their time now come?"
  67. Set a microbe to kill a microbe. Drug resistance renews interest in phage therapy, PD Thacker, JAMA 2003,290,3183-85
  68. Antibiotic development pipeline runs dry - new drugs to fight organisms are not being developed, experts say, R.Nelson, The Lancet 2003, 362, 1726-1727
  69. Resistant bacteria spread through US communities, Reprinted from The Lancet, Vol 362, Michael McCarthy, Resistant bacteria spread through, 1554-1555, Copyright (2003), with permission from Elsevier, http://www.thelancet.com
  70. Drug companies snub antibiotics as pipeline threatens to run dry, T.Clarke, Nature 2003, 425, 225
  71. The prospect for bacteriophage therapy in Western medicine, Merril CR, Scholl D, Adhya SL, Nat Rev Drug Discov. 2003, 2, 489-97
  72. Phage Therapy: a Reappraisal of Bacteriophages as Antibiotics, Jameel M. Inal, Arch. Immunol. Ther. Exp., 2003, 51, 237-244
  73. Bacteriophages - new antibiotics, Lancet Infect. Dis. 2003, 3, 394
  74. Bacteriophages: Potential Treatment for Bacterial Infections, Biodrugs 2002, 16, 57-62
  75. Stalin’s Forgotten Cure, SCIENCE 2002, 298, 728-731
  76. Bacteriophage therapy offers new hope for streptococcal infections, The Lancet, 2001, 357, 938
  77. The return of the phage, J. Wakefield, Smithsonian Magazine 2000 (October)
  78. Does antibacterial treatment for urinary tract infection contribute to the risk of breast cancer?, Knekt P, Adlercreutz H, Rissanen H, Aromaa A, Teppo L, Heliovaara M, Br J Cancer, 2000, 82, 1107-10
  79. Phage therapy - advantages over antibiotics?, The Lancet, 2000, 356, 1418
  80. Phage Therapy: Past History and Future Prospects, Richard M. Carlton, Arch. Immunol. Ther. Exp., 1999, 47, 267–274
  81. The presence in normal serum of specific antibody against bacteriophage T4 and its increase during the earliest stages of immunization,
    Jerne NK, J Immunol., 1956, 76(3), 209-16
  82. The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: reversible and irreversible inactivation,
    Jerne NK, Avegno P, J Immunol., 1956, 76(3), 200-8
  83. The rate of inactivation of bacteriophage T4r in specific anti-serum. I. Salt effect. II. Cofactor,
    Jerne NK, Skovsted L, Ann Inst Pasteur (Paris), 1953, 84(1),73-89
  84. Bacteriophage inactivation by antiphage serum diluted in distilled water,
    Jerne NK, Nature, 1952, 169(4290), 117-8